Clinical operations

When Illness Interrupts an Oncology Trial Visit

How oncology trial teams can respond to an interrupted visit, protect safety follow-up and document which assessments can still be completed.

By Lampgen Clinical Research

A hand rests on a planner beside the title “When illness interrupts an oncology trial visit.” In the illustrated scenario, a participant is hospitalized on the day of a study scan. The graphic advises teams to alert the investigator, check assessment windows and confirm the patient’s follow-up wishes.
An illustrated scenario for oncology trial teams.

3 min read · estimated

Sources
Scheduled assessmentsFeasible follow-up
A planning exercise for trial teams when a participant’s circumstances change.

What the source reported

An unexpected change in health can interrupt an oncology trial visit. The response starts with the investigator’s clinical assessment, a review of time-sensitive study activities and a conversation about what follow-up the participant wants.

In July 2026, journalist Samuel Braslow wrote that his treatments had lost effectiveness in parts of his body. In the same essay, he shared his plans to marry Kalie-Ann Nassoura. An excerpt from Sadiba Hasan’s November 5 New York Times feature describes the couple spending Halloween in a hospital room after his health changed suddenly. Their accounts put the unpredictability of serious illness in personal terms.

For trial teams, consider a separate, hypothetical scenario. A participant is admitted to a local hospital on the day of a study scan, safety labs and a symptom questionnaire. Each activity has its own purpose and timing. Plan who assesses the clinical and reporting implications, who checks the protocol and who speaks with the participant about the next step.

What this means for trial teams

Separate the clinical response from the visit logistics. The site should route the change in health to the investigator and follow the study’s safety reporting procedures. Review the assessment windows and whether each activity can be performed as planned, rescheduled within the window or handled through an approved option. FDA’s final guidance on decentralized elements describes telehealth and local providers for suitable trial activities. A remote conversation and a scan for central review have different requirements. A scan performed locally still needs to meet applicable acquisition and transfer specifications.

Confirm what the participant wants to continue. ICH E6(R3) distinguishes stopping an investigational intervention from withdrawing from a trial. The protocol should specify follow-up after treatment discontinuation. Explain the options clearly and respect the participant’s decision about further contact. If records from a local hospital are needed, use the approved consent and privacy process.

Make the handoff easy to audit. At site initiation, rehearse who alerts the investigator, checks the visit window, explains permitted options and documents the outcome. During monitoring, an oncology clinical research associate can review whether missed activities and safety follow-up were documented, including timing and relevant deviations. The clinical trial manager can look across sites for recurring gaps and bring possible changes to the appropriate study teams for review.

Look for patterns in who can use the available options. NCI identifies travel and caregiving among the costs patients may face when taking part in trials. Review documented reasons for missed visits by activity and site, which approved options were offered and whether participants could use them. Consider travel, work schedules and digital access when interpreting the pattern. Missing documentation leaves the reason unknown. A follow-up option helps only when the participant can use it and it meets the clinical and measurement requirements.

A useful site-readiness check is whether the team can trace one interrupted visit from first contact to documented outcome. That exercise can reveal where a study needs clearer escalation, better support for participants or a workable way to complete a time-sensitive assessment.

Sources

  1. Samuel Braslow, first-person account of treatment and wedding plans, July 10, 2026
  2. Sadiba Hasan, New York Times wedding feature, November 5, 2026
  3. Accessible excerpt of Sadiba Hasan’s reporting, Muck Rack
  4. FDA, final guidance on conducting clinical trials with decentralized elements, September 2024
  5. FDA and ICH, E6(R3) Good Clinical Practice, September 2025
  6. National Cancer Institute, Who Pays for Clinical Trials?
  7. Related Lampgen insight on trial participation burden and access
  8. Lampgen oncology CRA staffing

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?